卡培他滨+顺铂结合恩度治疗鼻咽癌的疗效观察

Efficacy of Capecitabine+Cisplatin Combined with Endostar in Treatment of Nasopharyngeal Carcinoma

目的:探讨卡培他滨结合恩度治疗鼻咽癌的疗效。方法:回顾性分析2017年3月至2019年3月在本院治疗的60例晚期鼻咽癌患者临床资料,根据治疗方案不同分为观察组(卡培他滨Q3W方案+恩度治疗,28例)和对照组(卡培他滨Q3W方案,32例)。比较两组临床治疗效果以及不良反应发生率。结果:治疗结束后,观察组疾病控制率高于对照组,差异有统计学意义(P<0.05);治疗期间,观察组毒副作用级别、总体不良反应与对照组比较,差异无统计学意义(P>0.05)。结论:卡培他滨结合恩度治疗可提升鼻咽癌患者治疗的疾病控制率,且不会明显增加不良反应发生率及毒副作用严重程度,安全性能高。

Objective:To investigate the efficacy of capecitabine combined with endostar in treatment of nasopharyngeal carcinoma.Methods:The clinical data of 60 patients with advanced nasopharyngeal carcinoma who treated in the hospital from March 2017 to March 2019 were retrospectively analyzed,and they were divided into observation group(capecitabine Q3W regimen and endostar,28 cases)and control group(capecitabine Q3W regimen,32 cases)according to treatment methods.The clinical curative effects and the incidence of adverse reactions were compared between two groups.Results:After treatment,the remission rate of observation group was higher than that of control group(P<0.05);There was no statistical difference in the degree of toxic-side effects and total adverse reactions between two groups during treatment(P>0.05).Conclusion:Capecitabine combined with endostar in treatment of patients with nasopharyngeal carcinoma can increase remission rate,and not increase the incidence of adverse reactions and severity of toxic-side effects,which has high safety.